1 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Hematological Malignancy: new trials by email Literature Review of Hematological Malignancy trials Research Report on Hematological Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents - Solid Tumor, Hematological Malignancy | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2019-09-15 | 2022-04-13 |
Cytokine Release Syndrome (1) · Hematologic Neoplasms (1)
Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Inflammation (1) · Neoplasms (1) · Neoplasms by Site (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Shock (1) · Systemic Inflammatory Response Syndrome (1)
Etanercept (1) · Infliximab (1) · Metoprolol (1)
Chinese PLA General Hospital (1)
China (1)